智通财经APP讯，翰思艾泰-B(03378)发布截至2025年12月31日止财政年度全年业绩，集团其他收入及收益人民币1661.6万元，同比增长116.33%;研发开支8936.3万元，同比增加19.6%;净亏损1.31亿元，同比扩大12.46%。
本公司核心竞争力源于聚焦独特的生物学原理和两大自主研发的专有生物新药创新平台 —VersatiBody™多功能抗体平台与autoRx40™自身免疫治疗平台，以此协同驱动差异化候选药物的高效研发与输出，同时通过内部自主研发+外部战略合作的双轮模式，持续丰富产品管线、加速临床开发进程、放大技术平台商业价值。截至2025年12月31日，本公司已建立“临床阶段(3款)+IND批准阶段(1款)+临床前阶段(多款)”的阶梯式产品管线布局，其中肿瘤免疫双特异性抗体、OX40靶向ADC等核心资产具备全球FIC潜力，为本公司长期发展奠定坚实的产品基础。2025年，本公司围绕管线临床推进、技术平台迭代、全球化布局完成多项关键里程碑，核心资产临床价值初步验证，为股东创造了阶段性价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.